Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings over 20 years of neuroscience-focused medical affairs leadership, having held senior positions at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His expertise is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
The appointment comes as Helus Pharma progresses its lead candidate, HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Both programs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma's NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to improve the treatment landscape through durable improvements in mental health. With Dr. Kramer's leadership in medical affairs, Helus expects to enhance its strategic collaborations and regulatory interactions.
For more details on the appointment, visit the full press release at https://ibn.fm/FdEXH. For ongoing updates, the company's newsroom is available at https://ibn.fm/HELP.
